Install
Your go-to source for the latest news in health, science and medicine. Sign up for STAT+ for exclusive analysis of biotech, pharma, and the life sciences.
- 3,855articles · 365d
- 3+ hour agolatest article
- Sep 15, 2025earliest in window
- 95%with images
- 271avg words
- Medical 2,628
- Health & Wellness 2,514
- Health 1,832
- Business & Industrial 894
- Science & Technology 720
- Economy, Business & Finance 571
- Politics2 435
- Politics 412
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Novo Nordisk’s high-dose Wegovy approved in the U.S.
5+ mon, 3+ week ago (168+ words) Elaine Chen, a national biotech reporter, is the co-author of The Readout, a newsletter about the business, science, and politics of biotech. A high-dose version of Novo Nordisk’s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing…...
NIH will spend its full budget this year, agency director promises House appropriators
5+ mon, 3+ week ago (142+ words) National Institutes of Health Director Jay Bhattacharya promised a House Appropriations subcommittee on Tuesday that, despite the sluggish pace of grant awards, the agency will spend its full budget by the end of the 2026 fiscal year. Roughly halfway through the…...
Science Corp. raises $230 million to bring retinal implant to Americans
6+ mon, 1+ week ago (128+ words) Science Corporation announced Thursday that the company raised $230 million as it awaits a decision from the Food and Drug Administration on PRIMA, their wireless retinal implant. The Series C funding round includes investors from Lightspeed Venture Partners, Khosla Ventures, Y…...
Could U.S. policy clinch China’s grip on biotech?
6+ mon, 1+ week ago (726+ words) Produced by STAT Brand Studio That’s the perspective of John Stanford, founder and executive director of Incubate, a coalition of early-stage life sciences investors. He warns that the Trump administration’s drug policy, including most-favored-nation — and regulatory uncertainty writ large — risks…...
Biotech doubles financing in quest to silence genes behind neurological diseases
7+ mon, 4+ day ago (256+ words) Allison DeAngelis is a biotech reporter at STAT, covering biopharma startups and venture capital. She is also co-host of the weekly biotech podcast, The Readout Loud. Prior to joining STAT, Allison covered the drug industry at Business Insider and the…...
Investor behind Moderna says U.S. policy is ‘taking a sledgehammer to our miracle machine’
8+ mon, 1+ day ago (110+ words) Test your knowledge with our new weekday mini crossword SAN FRANCISCO — Noubar Afeyan, one of biotech’s top investors, warned in an annual letter to investors that a backlash against science in the U.S. could endanger U.S. life expectancy,…...
As superbug fears grow, sales of antibiotics used in food-producing livestock rose dramatically last year
9+ mon, 1+ day ago (312+ words) Ed Silverman is a senior writer and Pharmalot columnist at STAT, and has covered the pharmaceutical industry for three decades. Prior to joining STAT at its founding in 2015, he worked at The Wall Street Journal, The Star-Ledger of New Jersey,…...
Top contributors to leading psychiatry journals fail to disclose industry payments, analysis finds
9+ mon, 1+ week ago (288+ words) Ed Silverman is a senior writer and Pharmalot columnist at STAT, and has covered the pharmaceutical industry for three decades. Prior to joining STAT at its founding in 2015, he worked at The Wall Street Journal, The Star-Ledger of New Jersey,…...
Recursion’s incoming CEO: Beyond hype on AI-driven drug development, it’s time to show results
9+ mon, 3+ week ago (121+ words) LONDON — In the year-plus since Najat Khan joined the AI-focused drug developer Recursion Pharmaceuticals, she has helped push forward — and prune — the company’s pipeline, and navigate its merger with Exscientia. Now Khan, who was hired as Recursion’s chief commercial officer…...
Scandal and controversy take toll on FDA credibility
10+ mon, 1+ week ago (66+ words) Good morning. We’ve got another busy week of earnings — Pfizer reported this morning and Novo Nordisk will be reporting tomorrow. We’ll be watching for any discussion on the Metsera bidding war. We’re also continuing to track the fallout from all…...